PL1692516T3 - Sposób terapii - Google Patents
Sposób terapiiInfo
- Publication number
- PL1692516T3 PL1692516T3 PL04761461T PL04761461T PL1692516T3 PL 1692516 T3 PL1692516 T3 PL 1692516T3 PL 04761461 T PL04761461 T PL 04761461T PL 04761461 T PL04761461 T PL 04761461T PL 1692516 T3 PL1692516 T3 PL 1692516T3
- Authority
- PL
- Poland
- Prior art keywords
- present
- diseases
- therapy
- production
- relates
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003905858A AU2003905858A0 (en) | 2003-10-24 | Method of therapy | |
PCT/AU2004/001456 WO2005040816A1 (en) | 2003-10-24 | 2004-10-22 | Method of therapy |
EP04761461A EP1692516B1 (en) | 2003-10-24 | 2004-10-22 | Method of therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1692516T3 true PL1692516T3 (pl) | 2011-05-31 |
Family
ID=34468632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL04761461T PL1692516T3 (pl) | 2003-10-24 | 2004-10-22 | Sposób terapii |
Country Status (16)
Country | Link |
---|---|
US (5) | US20070202119A1 (pl) |
EP (2) | EP2270511A3 (pl) |
JP (2) | JP4931593B2 (pl) |
CN (1) | CN1898569A (pl) |
AT (1) | ATE490470T1 (pl) |
BR (1) | BRPI0415533A (pl) |
CA (1) | CA2543490A1 (pl) |
DE (1) | DE602004030369D1 (pl) |
DK (1) | DK1692516T3 (pl) |
ES (1) | ES2357430T3 (pl) |
IL (1) | IL175141A0 (pl) |
NZ (1) | NZ546873A (pl) |
PL (1) | PL1692516T3 (pl) |
PT (1) | PT1692516E (pl) |
RU (1) | RU2006117793A (pl) |
WO (1) | WO2005040816A1 (pl) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPS065002A0 (en) * | 2002-02-20 | 2002-03-14 | Immunaid Pty Ltd | Strategy for retroviral immunotherapy |
US20030228320A1 (en) * | 2000-08-18 | 2003-12-11 | Ashdown Martin Leonard | Retroviral immunotherapy |
AUPS054702A0 (en) * | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
CN1898569A (zh) | 2003-10-24 | 2007-01-17 | 伊缪因艾德有限公司 | 治疗方法 |
PL1805510T3 (pl) * | 2004-09-08 | 2012-07-31 | Immunaid Pty Ltd | Strategia terapeutyczna leczenia chorób autoimmunologicznych i zwyrodnieniowych |
AU2005282218B2 (en) * | 2004-09-08 | 2012-04-12 | Biotempus Pty Ltd | Therapeutic strategy for treating autoimmune and degenerative diseases |
US8775207B2 (en) * | 2005-02-02 | 2014-07-08 | Siemens Medical Solutions Usa, Inc. | Integrated treatment planning and scheduling system |
DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
JP2012517607A (ja) * | 2009-02-20 | 2012-08-02 | オンコノム,インコーポレイテッド | 大腸癌の診断及び予後判定のための用具セット及び方法 |
ES2548508T3 (es) | 2009-05-27 | 2015-10-19 | Biotempus Limited | Métodos de tratamiento de enfermedades |
SG168431A1 (en) * | 2009-07-23 | 2011-02-28 | Univ Singapore | Cancer biomarker and the use thereof |
WO2011028683A1 (en) | 2009-09-03 | 2011-03-10 | Schering Corporation | Anti-gitr antibodies |
GB0920258D0 (en) * | 2009-11-19 | 2010-01-06 | Alligator Bioscience Ab | New medical agents and use thereof |
AU2010332283B2 (en) * | 2009-12-17 | 2014-06-12 | Mayo Foundation For Medical Education And Research | Determination of favorable time(s) for chemotherapy delivery |
SI3892295T1 (sl) | 2011-05-24 | 2023-09-29 | BioNTech SE | Individualizirana cepiva proti raku |
WO2013059638A1 (en) | 2011-10-21 | 2013-04-25 | Abbvie Inc. | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
CN103826627B (zh) | 2011-10-21 | 2016-02-24 | 艾伯维公司 | 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途 |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
EP2862111A4 (en) * | 2012-06-18 | 2016-01-20 | Mayo Foundation | DETERMINATION OF EFFICIENT TIMES FOR THE ADMINISTRATION OF CHEMOTHERAPY |
KR101534462B1 (ko) * | 2012-07-31 | 2015-07-06 | 한림대학교 산학협력단 | 사이클린 a2 저해제를 포함하는 c형간염 예방 및 치료용 조성물 |
WO2014082729A1 (en) | 2012-11-28 | 2014-06-05 | Biontech Ag | Individualized vaccines for cancer |
WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
CN103941021B (zh) * | 2014-05-09 | 2017-02-01 | 深圳市国赛生物技术有限公司 | 一种检测白细胞介素‑6的试剂盒以及非诊断目的检测白细胞介素‑6的方法 |
PL3148579T3 (pl) | 2014-05-28 | 2021-07-19 | Agenus Inc. | Przeciwciała anty-gitr i sposoby ich zastosowania |
EP3195168B1 (en) * | 2014-07-31 | 2022-09-07 | The University Of Western Australia | A method for the identification of immunotherapy-drug combinations using a network approach |
WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
MX2017007142A (es) * | 2014-12-05 | 2017-10-11 | Lifecycle Tech Pty Ltd | Metodo y sistema para mejorar una respuesta fisiologica. |
WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
JP2016148623A (ja) * | 2015-02-13 | 2016-08-18 | 京都府公立大学法人 | 大腸がんの検出方法 |
WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
US11447557B2 (en) | 2015-12-02 | 2022-09-20 | Agenus Inc. | Antibodies and methods of use thereof |
JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
US5308626A (en) * | 1985-06-28 | 1994-05-03 | Toni N. Mariani | Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
US5141867A (en) * | 1987-02-02 | 1992-08-25 | E. I. Du Pont De Nemours And Company | Nucleotide sequence encoding a human immunodeficiency virus antigen |
US5057423A (en) * | 1987-12-18 | 1991-10-15 | University Of Pittsburgh | Method for the preparation of pure LAK-active lymphocytes |
DE3812605A1 (de) | 1988-04-15 | 1990-06-07 | Leskovar Peter Dipl Ing Dr Hab | Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes |
US20020094542A1 (en) * | 1988-04-15 | 2002-07-18 | Peter Leskovar | Drugs and methods for treating cancer |
AU622926B2 (en) | 1988-09-09 | 1992-04-30 | Nippon Kayaku Kabushiki Kaisha | Pyrimidine or purine cyclobutane derivatives |
ATE135113T1 (de) | 1988-12-20 | 1996-03-15 | Clarity Technologies Inc | Synthetische hiv ähnliche peptide, deren zusammensetzungen und verwendungen |
US6248574B1 (en) | 1989-12-13 | 2001-06-19 | Avigdor Shaffermann | Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5925643A (en) | 1990-12-05 | 1999-07-20 | Emory University | Enantiomerically pure β-D-dioxolane-nucleosides |
IL102092A (en) | 1991-06-11 | 1996-11-14 | Microgenesys Inc | Use of recombinant VIH protein wrapped in VIH abduction drug and a pharmaceutical preparation containing the accumulated protein |
DE4120296A1 (de) | 1991-06-28 | 1992-03-19 | Regina Tilgner | Rein pflanzliches kombinationspraeparat - gegen aids |
US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
WO1994007921A1 (en) | 1992-09-25 | 1994-04-14 | Commonwealth Scientific And Industrial Research Organisation | Target binding polypeptide |
US5358852A (en) * | 1992-12-21 | 1994-10-25 | Eastman Kodak Company | Use of calcium in immunoassay for measurement of C-reactive protein |
DE69536091D1 (de) | 1994-01-27 | 2010-09-09 | Univ Massachusetts Medical | Immunisierung durch Impfung von DNS Transkriptionseinheit |
MY115461A (en) | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
IL117574A0 (en) | 1995-04-03 | 1996-07-23 | Bristol Myers Squibb Co | Processes for the preparation of cyclobutanone derivatives |
AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
US5939400A (en) | 1996-02-26 | 1999-08-17 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for induction of suppressive T cell response |
WO1997044446A1 (en) * | 1996-05-24 | 1997-11-27 | University Of Maryland At Baltimore | Dna vaccines for eliciting a mucosal immune response |
US20040203024A1 (en) | 1996-06-06 | 2004-10-14 | Baker Brenda F. | Modified oligonucleotides for use in RNA interference |
ZA975889B (en) * | 1996-07-08 | 1998-02-23 | Genentech Inc | HIV envelope polypeptides and vaccine. |
US6107020A (en) * | 1996-09-20 | 2000-08-22 | Roger Williams Hospital | Model for protective and pathogenic roles of HIV-1 env-directed antibody dependent cellular cytotoxicity interaction with viral load, and uses thereof |
US7030152B1 (en) * | 1997-04-02 | 2006-04-18 | The Brigham And Women's Hospital, Inc. | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
JPH11271304A (ja) * | 1998-03-24 | 1999-10-08 | Jcr Pharmaceuticals Co Ltd | Hiv感染の診断方法 |
WO1999064626A2 (en) * | 1998-06-06 | 1999-12-16 | Genostic Pharma Limited | Probes used for genetic profiling |
AU779494B2 (en) * | 1999-07-28 | 2005-01-27 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Immunotherapy in HIV infected persons using vaccines after multi-drug treatment |
US20040022787A1 (en) * | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
AUPS065002A0 (en) * | 2002-02-20 | 2002-03-14 | Immunaid Pty Ltd | Strategy for retroviral immunotherapy |
AUPQ948800A0 (en) * | 2000-08-18 | 2000-09-07 | Immunaid Pty Ltd | A vaccine strategy |
US20030228320A1 (en) * | 2000-08-18 | 2003-12-11 | Ashdown Martin Leonard | Retroviral immunotherapy |
AU2002215734A1 (en) | 2000-12-08 | 2002-06-18 | University Technologies International Inc. | Nrp-derived peptides useful for treating insulin-dependent diabetes mellitus |
AUPS054702A0 (en) * | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
US20060134713A1 (en) * | 2002-03-21 | 2006-06-22 | Lifescan, Inc. | Biosensor apparatus and methods of use |
NZ540779A (en) * | 2002-11-01 | 2008-05-30 | Univ Pennsylvania | Compositions and methods for siRNA inhibition of HIF-1 alpha |
WO2004042027A2 (en) | 2002-11-04 | 2004-05-21 | University Of Massachusetts | Allele-specific rna interference |
AU2004209984B2 (en) | 2003-01-31 | 2010-08-05 | Albor Biologics, Inc. | Immune regulation based on the targeting of early activation molecules |
AU2003279088A1 (en) | 2003-09-10 | 2005-04-27 | Chiron Corporation | Prion chimeras and uses thereof |
CN1898569A (zh) | 2003-10-24 | 2007-01-17 | 伊缪因艾德有限公司 | 治疗方法 |
CN1953767B (zh) | 2004-01-08 | 2011-03-16 | 加利福尼亚大学董事会 | 调节t细胞抑制自身免疫 |
JP2007522119A (ja) | 2004-01-28 | 2007-08-09 | キュリックス エーピーエス | アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート |
PL1805510T3 (pl) | 2004-09-08 | 2012-07-31 | Immunaid Pty Ltd | Strategia terapeutyczna leczenia chorób autoimmunologicznych i zwyrodnieniowych |
GB2436616A (en) * | 2006-03-29 | 2007-10-03 | Inverness Medical Switzerland | Assay device and method |
US8131325B2 (en) * | 2009-02-27 | 2012-03-06 | Research In Motion Limited | Method, apparatus and system for battery resource management via traffic steering |
ES2548508T3 (es) * | 2009-05-27 | 2015-10-19 | Biotempus Limited | Métodos de tratamiento de enfermedades |
-
2004
- 2004-10-22 CN CNA2004800389993A patent/CN1898569A/zh active Pending
- 2004-10-22 ES ES04761461T patent/ES2357430T3/es active Active
- 2004-10-22 WO PCT/AU2004/001456 patent/WO2005040816A1/en active Application Filing
- 2004-10-22 JP JP2006535913A patent/JP4931593B2/ja not_active Expired - Fee Related
- 2004-10-22 BR BRPI0415533-5A patent/BRPI0415533A/pt not_active Application Discontinuation
- 2004-10-22 RU RU2006117793/15A patent/RU2006117793A/ru unknown
- 2004-10-22 PT PT04761461T patent/PT1692516E/pt unknown
- 2004-10-22 DK DK04761461.5T patent/DK1692516T3/da active
- 2004-10-22 US US10/576,981 patent/US20070202119A1/en not_active Abandoned
- 2004-10-22 CA CA002543490A patent/CA2543490A1/en not_active Abandoned
- 2004-10-22 EP EP10180749A patent/EP2270511A3/en not_active Withdrawn
- 2004-10-22 NZ NZ546873A patent/NZ546873A/en not_active IP Right Cessation
- 2004-10-22 AT AT04761461T patent/ATE490470T1/de active
- 2004-10-22 EP EP04761461A patent/EP1692516B1/en active Active
- 2004-10-22 DE DE602004030369T patent/DE602004030369D1/de active Active
- 2004-10-22 PL PL04761461T patent/PL1692516T3/pl unknown
-
2006
- 2006-04-24 IL IL175141A patent/IL175141A0/en unknown
-
2011
- 2011-12-09 JP JP2011269612A patent/JP5616880B2/ja not_active Expired - Fee Related
-
2012
- 2012-02-14 US US13/396,254 patent/US8524651B2/en active Active
-
2013
- 2013-10-24 US US14/061,937 patent/US20140051100A1/en not_active Abandoned
- 2013-10-25 US US14/063,104 patent/US20140065644A1/en not_active Abandoned
-
2015
- 2015-09-03 US US14/844,882 patent/US20150377882A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2543490A1 (en) | 2005-05-06 |
CN1898569A (zh) | 2007-01-17 |
RU2006117793A (ru) | 2007-12-10 |
US20140065644A1 (en) | 2014-03-06 |
EP2270511A3 (en) | 2011-08-24 |
EP1692516A1 (en) | 2006-08-23 |
EP2270511A2 (en) | 2011-01-05 |
DE602004030369D1 (de) | 2011-01-13 |
EP1692516B1 (en) | 2010-12-01 |
JP4931593B2 (ja) | 2012-05-16 |
JP5616880B2 (ja) | 2014-10-29 |
ES2357430T3 (es) | 2011-04-26 |
US20070202119A1 (en) | 2007-08-30 |
ATE490470T1 (de) | 2010-12-15 |
JP2012093366A (ja) | 2012-05-17 |
DK1692516T3 (da) | 2011-02-28 |
US20140051100A1 (en) | 2014-02-20 |
US20120156225A1 (en) | 2012-06-21 |
PT1692516E (pt) | 2011-03-07 |
BRPI0415533A (pt) | 2006-12-26 |
JP2007509078A (ja) | 2007-04-12 |
EP1692516A4 (en) | 2008-09-24 |
IL175141A0 (en) | 2006-09-05 |
US8524651B2 (en) | 2013-09-03 |
NZ546873A (en) | 2010-09-30 |
US20150377882A1 (en) | 2015-12-31 |
WO2005040816A1 (en) | 2005-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL175141A0 (en) | Method of therapy | |
WO2005034843A3 (en) | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders | |
WO2004074457A3 (en) | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions | |
EP2465923A3 (en) | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions | |
WO2006014159A3 (en) | Methods of using regenerative cells in the treatment of musculoskeletal disorders | |
GB0223380D0 (en) | Combination therapy | |
WO2005065242A3 (en) | Method of treating cancer using platelet releasate | |
PT1782825E (pt) | Tratamento de doenças de armazenanto de glicogénio tipo ii | |
WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
WO2008157787A3 (en) | Hydroxylated tolans and related compounds in the treatment of cancer | |
ATE546733T1 (de) | Therapiestrategie zur behandlung von autoimmunkrankheiten und degenerativen erkrankungen | |
ATE535237T1 (de) | Verwendung von fts zur behandlung von malignen erkrankungen | |
WO2006022612A3 (en) | Methods of using regenerative cells in the treatment of stroke and related diseases and disorders | |
WO2003057162A3 (en) | Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases | |
WO2018020285A3 (en) | Flow capture device and method for removing cells from blood | |
SI1596879T1 (sl) | Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice | |
IL159770A0 (en) | Calcium salts with cytotoxic activity | |
AU1601499A (en) | Citicoline to treat motor neuron diseases and demyelinating diseases | |
WO2006014162A3 (en) | Methods of using regenerative cells in the treatment of renal diseases and disorders | |
WO2003032895A3 (en) | Methods and pharmaceutical compositions for stimulating the immune system and/or treating cancer | |
RU98105539A (ru) | Способ лечения псориаза | |
Bakhtar | Amazing Topical Protocol and Novel Powder Dressing Combination Formula in Treatment of Diabetic Foot Wounds. | |
RU2008142658A (ru) | Способ лечения инфекционных поражений нервной системы | |
RU2003101445A (ru) | Способ лечения атопической бронхиальной астмы | |
曲雅文 et al. | Observation on Clinical Effect of Angelica Injection in Treating Cerebral Infarction Sequela Through Stimulating Nerve Root |